BURLINGAME, Calif.--(BUSINESS WIRE)--Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, announced that the U.S. Food and Drug Administration (FDA) ...
SAN MATEO, Calif.--(BUSINESS WIRE)--Cala, the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced meeting the primary endpoint on an interim analysis of a ...
SAN MATEO, Calif. and HONOLULU, Oct. 6, 2025 /PRNewswire/ — Cala ®, the bioelectronic medicine leader, announced today the publication of a groundbreaking study in the journal Brain Stimulation ...
SAN MATEO, Calif., April 7, 2025 /PRNewswire/ -- Cala, the bioelectronic medicine leader, who recently raised an oversubscribed growth financing round and was recognized on Fast Company's annual top ...
"I am excited to be serving as the CEO for Cala as we significantly expand access of Cala TAPS Therapy to Medicare patients who represent approximately 75% of the ET population." "It isexciting to see ...
SAN MATEO, Calif., Jan. 9, 2024 /PRNewswire/ -- Cala, the bioelectronic medicine leader, today announced the results from multiple clinical studies, further strengthening evidence supporting positive ...
Cala Health, a wearable neuromodulation therapy startup focused on chronic diseases, has closed a $50 million Series C financing round. Novartis, Baird Capital, LifeSci Venture Partners, TriVentures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results